Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus

Gastroenterology

Volumn 119, Issue 5, 2000, Pages 1382-1384

  Saab, Sammy ^a   Kim, Michael ^a   Wright, Teresa L ^b   Han, Steven H B ^b   Martin, Paul ^c   Busuttil, Ronald W ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CASE REPORT; DRUG EFFECT; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION; VIROLOGY;

HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034321472     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.19279     Document Type: Article

References (9)

1. Wright TL, Lau JYN. Clinical aspects of hepatitis B virus infection. Lancet 1993;342:1340-1344.
2. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, GOSS JA, Schmidt P, Pakrasi A, Imagawa DK, Holt C, Goldstein Ll, Stribling R, Busuttil RW. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998:28:585-589.
3. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai Dl, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998:339:61-68.
4. Alien Ml, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay L. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998:27:1670-1677.
5. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling J, Lok ASF. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998;27:213-222.
6. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Ascher NL, Wright TL. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;24:1327-1333.
7. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
8. Barthelomew MM, Jansen RW, Jeffers U, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tz NA. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22.
9. Nery JR, Weppler D, Rodriquez M, Ruiz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998;65:1615-1621.